IDEXX Laboratories (NASDAQ:IDXX) Price Target Lowered to $481.00 at Barclays

IDEXX Laboratories (NASDAQ:IDXX - Free Report) had its price target decreased by Barclays from $570.00 to $481.00 in a report released on Monday, Benzinga reports. Barclays currently has an overweight rating on the stock.

Other equities analysts have also issued research reports about the stock. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. Piper Sandler decreased their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a "neutral" rating on the stock in a report on Wednesday, August 14th. BTIG Research assumed coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a "buy" rating and a $580.00 target price for the company. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, July 10th. Finally, JPMorgan Chase & Co. cut their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $552.38.

IDEXX Laboratories Stock Down 0.7 %

Shares of IDXX stock traded down $2.76 on Monday, reaching $414.52. 923,551 shares of the company were exchanged, compared to its average volume of 492,806. The company has a market cap of $34.12 billion, a price-to-earnings ratio of 39.97, a PEG ratio of 3.55 and a beta of 1.36. The company has a 50-day moving average of $478.76 and a 200-day moving average of $487.19. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories has a one year low of $404.74 and a one year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period last year, the business posted $2.53 earnings per share. The business's revenue for the quarter was up 6.6% on a year-over-year basis. Analysts anticipate that IDEXX Laboratories will post 10.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in IDEXX Laboratories by 1.2% during the first quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company's stock worth $4,576,476,000 after buying an additional 98,387 shares during the period. American Century Companies Inc. increased its holdings in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after purchasing an additional 177,226 shares in the last quarter. International Assets Investment Management LLC raised its position in shares of IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after acquiring an additional 527,460 shares during the period. Dimensional Fund Advisors LP boosted its position in IDEXX Laboratories by 13.1% during the second quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock worth $249,855,000 after purchasing an additional 59,519 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in IDEXX Laboratories by 12.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company's stock valued at $190,283,000 after acquiring an additional 43,473 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.